CLGN
CollPlant Biotechnologies Ltd.
CLGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
CLGN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
CLGN's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
CLGN PE Valuation
CLGN has no meaningful PE right now: it lost money over the past year.
CLGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CLGN's losses to shrink, with revenue declining.
CLGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.39 | +$1.91 |
| Q1 2026 | -$10.30 | +$1.90 |
| Q4 2025 | -$9.30 | +$5.30 |
| Q3 2025 | -$10.20 | +$5.10 |
| Q2 2025 | -$11.30 | +$4.00 |
| Q1 2025 | -$12.20 | -$5.50 |
| Q4 2024 | -$14.60 | -$8.10 |
| Q3 2024 | -$15.30 | -$9.20 |
CLGN is still losing money, but far less than before: $9.39 per share over the past year, against $21.40 at its worst in late 2019.
CLGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $108K | -40% |
| Q1 2026 | $73K | -96% |
| Q4 2025 | $60K | -63% |
| Q3 2025 | $77K | +1825% |
| Q2 2025 | $179K | -28% |
| Q1 2025 | $2.1M | +1997% |
| Q4 2024 | $164K | -45% |
| Q3 2024 | $4K | -91% |
CLGN's revenue has slid since its 2021 peak: $108,000 last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2438% | -663 points |
| Q1 2026 | -4267% | -4187 points |
| Q4 2025 | -5250% | -2827 points |
| Q3 2025 | -4555% | +108995 points |
| Q2 2025 | -1775% | -5.9 points |
| Q1 2025 | -80% | +4337 points |
| Q4 2024 | -2423% | -728 points |
| Q3 2024 | -113550% | -102848 points |
CLGN's operating margin was −2438% last quarter, down 663 points from the same quarter a year ago.
CLGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.5M | -$99K |
| Q1 2026 | -$3.1M | -$1.9M |
| Q4 2025 | -$3.2M | +$296.9K |
| Q3 2025 | -$2.9M | +$710K |
| Q2 2025 | -$2.4M | +$1.7M |
| Q1 2025 | -$1.2M | +$2.2M |
| Q4 2024 | -$3.5M | -$949K |
| Q3 2024 | -$3.6M | -155% |
CLGN has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
CLGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +67.9K shares |
| 1 year | +22% | +259K shares |
| 3 years | +22% | +265K shares |
| 5 years | +41% | +423K shares |
| Available history | +209% | +976K shares |
CLGN has 1M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CLGN hasn't bought back shares in the past year.
CLGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -9.1x | Net Cash |
| Q3 2021 | -11.9x | Net Cash |
| Q2 2021 | -2.5x | Net Cash |
| Q1 2021 | -2.5x | Net Cash |
CLGN has more cash than debt.
CLGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 23.1 | Neutral |
CLGN's weekly RSI is 50 (neutral) and its Stochastic is 23 (neutral).
CLGN PE vs Healthcare Sector
CLGN has no meaningful PE right now: it lost money over the past year.
CLGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 19% above |
| 20 week MA | $3.63 | 28% above |
| 50 week MA | $6.53 | 29% below |
| 100 week MA | $16.3 | 72% below |
| 200 week MA | $39.0 | 88% below |
CLGN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 88% below its 200-week average.
CLGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.0 | $100.5 | +73% |
| 2021 | $100.5 | $132.2 | +32% |
| 2022 | $132.2 | $83.4 | -37% |
| 2023 | $83.4 | $63.9 | -23% |
| 2024 | $63.9 | $35.7 | -44% |
| 2025 | $35.7 | $15.3 | -57% |
| 2026 YTD | $15.3 | $4.64 | -70% |
CLGN has finished four years in a row lower, and it's down 70% so far in 2026.